Lakefront Biotherapeutics Gains 2.7% as Investors Back Its Clinical‑Stage Pipeline
Lakefront Biotherapeutics climbs 2.7% as investors focus on its clinical‑stage pipeline and partnership with Galapagos NV, signaling cautious bullish momentum in the biotech sector.
- LAKEFRONT BIOTHERAPEUTICS
- Belgium
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read